The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Its latest quarterly revenue reached 13.68M, representing a year-over-year decrease of 89.33%, while its net profit experienced a year-over-year decrease of 143.64%.
Key Metrics
The company’s current valuation score is 7.41, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is -0.08, which is -25.39% below the recent high of -0.06 and -5380.65% above the recent low of -4.53.
The company’s current earnings forecast score is 5.50, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Adaptimmune Therapeutics PLC is 0.28, with a high of 0.46 and a low of 0.09.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The company’s current price momentum score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.05. Sideways: Currently, the stock price is trading between the resistance level at 0.21 and the support level at -0.03, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The latest institutional shareholding proportion is 31.43%, representing a quarter-over-quarter decrease of 29.72%. The largest institutional shareholder is James Simons, holding a total of 1.88M shares, representing 0.71% of shares outstanding, with 28.05% decrease in holdings.
The company’s current risk assessment score is 1.04, which is lower than the Pharmaceuticals industry's average of 5.11. The company's beta value is 2.41. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
